Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer
Introduction: Whereas CDK4/6 inhibitors (CDK4/6i) are the standard first-line therapy for patients with hormone receptor-positive (HRpos), HER2-negative (HER2neg) metastatic breast cancer, guidelines on treatment options after progression on CDK4/6i are more diverse. Chemotherapy is recommended if a...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
9 September 2025
|
| In: |
European journal of cancer
Year: 2025, Jahrgang: 227, Pages: 1-9 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2025.115689 |
| Online-Zugang: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2025.115689 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S095980492500471X 
|
| Verfasserangaben: | Laura L. Michel, Markus Wallwiener, Andreas Schneeweiss [und viele weitere] |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1938365186 | ||
| 003 | DE-627 | ||
| 005 | 20260122084716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251014s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2025.115689 |2 doi | |
| 024 | 7 | |a 10.25673/120814 |2 doi | |
| 035 | |a (DE-627)1938365186 | ||
| 035 | |a (DE-599)KXP1938365186 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Michel, Laura L. |d 1984- |e VerfasserIn |0 (DE-588)1018124888 |0 (DE-627)680395857 |0 (DE-576)355064529 |4 aut | |
| 245 | 1 | 0 | |a Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer |c Laura L. Michel, Markus Wallwiener, Andreas Schneeweiss [und viele weitere] |
| 264 | 1 | |c 9 September 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 5. August 2025, Artikelversion: 7. August 2025 | ||
| 500 | |a Gesehen am 22.01.2026 | ||
| 520 | |a Introduction: Whereas CDK4/6 inhibitors (CDK4/6i) are the standard first-line therapy for patients with hormone receptor-positive (HRpos), HER2-negative (HER2neg) metastatic breast cancer, guidelines on treatment options after progression on CDK4/6i are more diverse. Chemotherapy is recommended if a patient develops endocrine resistance or experiences a visceral crisis. However, the impact of the choice of chemotherapy remains unknown. Methods: HRpos/HER2neg patients who received first-line CDK4/6i, followed by second-line chemotherapy (N=215) were selected from the prospective PRAEGNANT registry (NCT02338167). Cox regression analyses were used to evaluate the correlation between the choice of chemotherapy (capecitabine monotherapy, capecitabine + bevacizumab, taxane monotherapy, taxane + bevacizumab, anthracycline, other chemotherapeutics) and progression-free survival (PFS) and overall survival (OS). Results: Patients who received second-line chemotherapy mostly had high-grade tumors (G2: 62.3%, G3: 33.3%), visceral metastases (62.3%) and developed metastatic disease following a primary breast cancer diagnosis (73.8%). Capecitabine was the most common regimen (25.1%), followed by taxane +bevacizumab (17.2%). When adjusting for other prognostic factors (age, BMI, grading, ECOG, metastasis group and time to metastases), the choice of chemotherapy did not influence PFS (p=0.16) nor OS (p=0.47). Adjusted hazard ratios for PFS were lowest in regimens with bevacizumab (capecitabine as reference; capecitabine + bevacizumab: 0.53 (95%CI: 0.29, 0.97); taxane +bevacizumab: 0.64 (95%CI 0.35, 1.15)). Conclusion: Although the choice of chemotherapy post-CDK4/6i did not significantly affect PFS or OS, combinations with bevacizumab may have some benefit. Nevertheless, considering side effects may be most important when choosing the type of second-line chemotherapy. | ||
| 540 | |q DE-3 |a Namensnennung 4.0 International |f CC BY 4.0 |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 650 | 4 | |a CDK4/6 inhibitor | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Hormone receptor-positive | |
| 650 | 4 | |a Metastatic breast cancer | |
| 650 | 4 | |a Prognosis | |
| 700 | 1 | |a Wallwiener, Markus |d 1980- |e VerfasserIn |0 (DE-588)134044827 |0 (DE-627)692043934 |0 (DE-576)27468327X |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 227(2025) vom: Sept., Artikel-ID 115689, Seite 1-9 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer |
| 773 | 1 | 8 | |g volume:227 |g year:2025 |g month:09 |g elocationid:115689 |g pages:1-9 |g extent:9 |a Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2025.115689 |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S095980492500471X |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260122 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 32 | ||
| 998 | |g 134044827 |a Wallwiener, Markus |m 134044827:Wallwiener, Markus |d 50000 |e 50000PW134044827 |k 0/50000/ |p 2 | ||
| 998 | |g 1018124888 |a Michel, Laura L. |m 1018124888:Michel, Laura L. |d 910000 |d 910100 |e 910000PM1018124888 |e 910100PM1018124888 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1938365186 |e 485673489X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"pubHistory":["28.1992 -"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"part":{"volume":"227","year":"2025","extent":"9","pages":"1-9","text":"227(2025) vom: Sept., Artikel-ID 115689, Seite 1-9"},"language":["eng"],"titleAlt":[{"title":"EJC online"}],"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerEuropean journal of cancer","recId":"266883400","origin":[{"dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","publisher":"Elsevier ; Pergamon Press","dateIssuedDisp":"1992-"}],"id":{"issn":["1879-0852"],"eki":["266883400"],"zdb":["1468190-0"]},"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}]}],"origin":[{"dateIssuedDisp":"9 September 2025","dateIssuedKey":"2025"}],"title":[{"title":"Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer","title_sort":"Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1938365186"],"doi":["10.1016/j.ejca.2025.115689","10.25673/120814"]},"physDesc":[{"extent":"9 S.","noteIll":"Diagramme"}],"person":[{"role":"aut","family":"Michel","display":"Michel, Laura L.","given":"Laura L."},{"family":"Wallwiener","role":"aut","given":"Markus","display":"Wallwiener, Markus"},{"role":"aut","family":"Schneeweiss","given":"Andreas","display":"Schneeweiss, Andreas"}],"recId":"1938365186","note":["Online verfügbar: 5. August 2025, Artikelversion: 7. August 2025","Gesehen am 22.01.2026"],"language":["eng"],"name":{"displayForm":["Laura L. Michel, Markus Wallwiener, Andreas Schneeweiss [und viele weitere]"]}} | ||
| SRT | |a MICHELLAURPROGNOSTIC9202 | ||